Replies to post #35310 on Pluristem Therapeutics Inc (PSTI)

[Crustacener]

from the beforementioned article:

These preliminary findings support the use of remdesivir for patients who are hospitalized with Covid-19 and require supplemental oxygen therapy. However, given high mortality despite the use of remdesivir, it is clear that treatment with an antiviral drug alone is not likely to be sufficient. Future strategies should evaluate antiviral agents in combination with other therapeutic approaches or combinations of antiviral agents to continue to improve patient outcomes in Covid-19.

https://www.nejm.org/doi/full/10.1056/NEJMoa2007764

[skitahoe]

I think it was clear from the beginning that Remdisaver had benefits, but wouldn't greatly diminish the deaths, this really is confirming the earlier findings. There may be other products that compete with PLX-PAD, but I believe it's clearly above any of the products that are available today because they're approved for other applications.

It's not clear when 28 days will occur for the additional patients that compassionate use was granted for, but we certainly should hear something about them in the next couple weeks. What we don't know is how many more are getting the drug under compassionate use terms, I don't believe they've stopped the program of looking at it when it's applied for.

I'm uncertain if people who receive the drug under compassionate use pay anything, if they don't, getting it under compassionate use is better than getting into a trial, because you may get the placebo in the trial.

It may be August or September before we learn the trial results, though clinicians can stop trials early if they believe the benefits are great, and the outcome obvious, but this is a short trial in the first place, so it will probably go 28 days or more for all participants.

Gary